Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- DOCUMENT AND ENTITY INFORMATION
Financial Statements
Notes to Financial Statements
Notes Tables
Notes Details

Sponsored Research and License Agreements (Details)

v3.7.0.1

Sponsored Research and License Agreements (Details) - USD ($)	1 Months Ended			3 Months Ended
	Feb. 28, 2017	Jun. 30, 2016	Mar. 31, 2015	Mar. 31, 2017	Jun. 30, 2016	Mar. 31, 2016
Collaborative arrangement
Collaborations
Maximum amount of contingent payments receivable				$ 533,300,000
Specified Development Events \| Collaborative arrangement
Collaborations
Maximum amount of contingent payments receivable				146,400,000
Specified Regulatory Events \| Collaborative arrangement
Collaborations
Maximum amount of contingent payments receivable				345,600,000
Specified Product Launch Events \| Collaborative arrangement
Collaborations
Maximum amount of contingent payments receivable				41,300,000
Bristol-Myers Squibb Company
Collaborations
Noncreditable and nonrefundable upfront payment by BMS			$ 30,000,000
Revenue recognized						$ 4,800,000
Bristol-Myers Squibb Company \| Research Activities
Collaborations
Revenue recognized						$ 195,000
Bristol-Myers Squibb Company \| Minimum
Collaborations
Contingent payments				309,000,000
Ber Gen Bio A S
Collaborations
Upfront fee received	$ 3,300,000	$ 1,700,000
Revenue recognized				$ 3,300,000	$ 3,700,000
Payment received from exercise of option rights		$ 2,000,000

- Definition

Represents the maximum amount of pre-specified contingent payments receivable under the collaborative and licensing agreement.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementMaximumAmountOfContingentPaymentReceivable
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents payments received from exercise of option rights.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementOptionRightsExercised
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the revenue recognized during the period under the terms of sponsored research and license agreements.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementRevenueRecognized
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the amount of upfront fees received during the period under the terms of collaborative and licensing agreement.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementUpfrontFeeReceived
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents additional contingent payments by entities.

+ References

No definition available.

+ Details

Name:	rigl_ContingentPaymentsUnderAgreement
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the noncreditable and nonrefundable upfront payment.

+ References

No definition available.

+ Details

Name:	rigl_NonCreditableAndNonRefundableUpfrontPayment
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_SpecifiedDevelopmentEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_SpecifiedRegulatoryEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_SpecifiedProductLaunchEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=rigl_BristolMyersSquibbCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_ResearchActivitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=rigl_BerGenBioASMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: